We excluded such studies as the current standard of care for patients with FLT3‐mutated R/R AML is gilteritinib monotherapy, and we wanted to deduce the actual efficacy of the FLT3 inhibitor per se. Here, FLT3 is linked to acute myeloid leukemia.